Why the study?
Do mitochondria-targeting therapies slow down the progression of diabetic cardiomyopathy?
Do mitochondria-targeting therapies slow down the progression of diabetic cardiomyopathy?
Mitochondria-targeting therapies represent a potential strategy to slow the progression of diabetic cardiomyopathy.
Should not yet change practice in diabetic cardiomyopathy; leaves open the need for randomized trials of mitochondria-targeting therapies.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Dabravolski et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: